1. Home
  2. BDSX vs UNCY Comparison

BDSX vs UNCY Comparison

Compare BDSX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$22.15

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$5.26

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
UNCY
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.3M
145.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BDSX
UNCY
Price
$22.15
$5.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$32.50
$25.67
AVG Volume (30 Days)
89.7K
2.6M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$88,499,000.00
$675,000.00
Revenue This Year
$25.26
N/A
Revenue Next Year
$19.15
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.29
$3.72
52 Week High
$24.92
$8.74

Technical Indicators

Market Signals
Indicator
BDSX
UNCY
Relative Strength Index (RSI) 61.82 38.23
Support Level $6.63 $4.73
Resistance Level $24.92 $5.59
Average True Range (ATR) 2.39 0.76
MACD 0.01 -0.20
Stochastic Oscillator 71.93 29.81

Price Performance

Historical Comparison
BDSX
UNCY

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: